Viridian Therapeutics (NASDAQ:VRDN - Free Report ) in a report published on Thursday morning, Benzinga reports. Needham & Company LLC currently has a $30.00 price objective on the stock.
Get Viridian Therapeutics alerts:
Sign Up
A number of other analysts have also recently issued reports on VRDN. Wedbush increased their price objective on shares of Viridian Therapeutics from $39.00 to $40.00 and gave the stock an outperform rating in a research note on Wednesday, February 28th. B. Riley cut Viridian Therapeutics from a buy rating to a neutral rating and decreased their price target for the company from $25.00 to $20.00 in a report on Thursday. Finally, HC Wainwright reiterated a buy rating and set a $37.00 target price on shares of Viridian Therapeutics in a research report on Thursday, February 29th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of $34.60.
Read Our Latest Stock Report on Viridian Therapeutics
Viridian Therapeutics Stock Performance Viridian Therapeutics stock traded down $0.99 during trading on Thursday, reaching $13.91. The company had a trading volume of 1,729,471 shares, compared to its average volume of 927,377. The firm's 50-day simple moving average is $16.46 and its 200 day simple moving average is $17.64. Viridian Therapeutics has a 52 week low of $10.93 and a 52 week high of $28.35. The company has a current ratio of 18.26, a quick ratio of 18.26 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $887.74 million, a price-to-earnings ratio of -2.61 and a beta of 1.14.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report ) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.79) earnings per share for the quarter, beating analysts' consensus estimates of ($1.07) by $0.28. The firm had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.09 million. Viridian Therapeutics had a negative return on equity of 121.80% and a negative net margin of 75,711.48%. The business's quarterly revenue was down 26.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.61) EPS. Sell-side analysts forecast that Viridian Therapeutics will post -4.39 earnings per share for the current fiscal year.
Institutional Trading of Viridian Therapeutics A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VRDN. Vestal Point Capital LP purchased a new stake in shares of Viridian Therapeutics during the fourth quarter valued at $21,780,000. Perceptive Advisors LLC raised its stake in shares of Viridian Therapeutics by 71.1% during the fourth quarter. Perceptive Advisors LLC now owns 1,730,212 shares of the company's stock valued at $37,684,000 after acquiring an additional 719,007 shares in the last quarter. RTW Investments LP purchased a new stake in shares of Viridian Therapeutics in the fourth quarter valued at approximately $13,195,000. Braidwell LP raised its position in Viridian Therapeutics by 43.8% during the 3rd quarter. Braidwell LP now owns 1,735,182 shares of the company's stock valued at $26,618,000 after purchasing an additional 528,882 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Viridian Therapeutics by 170.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 313,217 shares of the company's stock worth $4,805,000 after buying an additional 197,430 shares during the period.
Viridian Therapeutics Company Profile (
Get Free Report )
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Featured Articles
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
